Advances with antibody-drug conjugates in breast cancer treatment-Reference-Cited by-同舟云学术

Advances with antibody-drug conjugates in breast cancer treatment

Published:2021-12 Issue: Volume:169 Page:241-255
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Abdus Subhan Md,Torchilin Vladimir P.

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference131 articles.

1. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin;Cianfriglia;Ann. Ist. Super Sanità,2013

2. Antibody-drug-conjugates for cancer therapy;Carter;Cancer J.,2008

3. Monoclonal antibodies in cancer therapy: 25 years of progress;Oldham;J. Clin. Oncol.,2008

4. Monoclonal antibody therapy of cancer;Goldenberg;N. Engl. J. Med.,1990

5. Antibody therapy of cancer;Scott;Nat. Rev. Cancer,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy;Bioengineering;2024-08-14

2. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?;Journal of Medicinal Chemistry;2024-07-09

3. Triple-Negative Breast Cancer Therapy: Recent Advances, Challenges, and Future Perspective;Interdisciplinary Cancer Research;2023

4. Antibody–drug conjugate: Emerging trend for targeted treatment;Polymer-Drug Conjugates;2023

5. Special issue on the latest advances in regenerative medicine and cancer using drug delivery systems;European Journal of Pharmaceutics and Biopharmaceutics;2022-08